



BioLight Files Registration Statement for Proposed Initial Public Offering in the United States

TEL AVIV (February 10, 2016) - BioLight Life Sciences Ltd. (TASE:BOLT; OTCQX:BLGTY) ("BioLight" or the "Company") today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering. The number of the securities to be offered and the price range for the proposed offering have not yet been determined. BioLight has applied to list its ordinary shares on the NASDAQ Capital Market under the ticker symbol "BOLT."

Feltl and Company, Inc. and Rodman & Renshaw, a unit of H.C. Wainwright & Co., are acting as joint book-running managers in the offering.

The offering will be made only by means of a prospectus. A preliminary prospectus for the offering, when available, may be obtained from contacting Feltl and Company, Inc., Prospectus Department, 800 LaSalle Avenue, 2100 LaSalle Plaza, Minneapolis, MN 55402, telephone: 612-492-8800, e-mail: prospectus@feltl.com or Rodman & Renshaw, a unit of H.C. Wainwright & Co., 430 Park Avenue, 4th Floor, New York, NY 10022, email: placements@hwcwco.com.

A registration statement related to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The registration statement can be accessed through the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.